Hot Investor Mandate: Canada VC Firm Invests in Early-Stage Technologies that Enable Higher Quality Personalized Treatments, Open to Global Opportunities

9 Jul

A venture capital firm with offices in Canada will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital.

The firm has a general theme of investing in technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email

RESI 2-Day Partnering Event – Partnering Goes Live July 13!

9 Jul

By Karen Deyo, Senior Investor Research Analyst, LSN

The RESI 2-Day Partnering Event is just over two weeks away, and we are launching the Partnering Platform on Monday, July 13! With a 50% increase in registered attendees over our last Dedicated Partnering Event, with participants representing over 20 countries on 4 continents, the partnering event is a testament to RESI’s global reach, and our ability to help startups and investors connect from their home offices and keep the dialogue going. Registered companies span the 4Ds: Drugs, Devices, Diagnostics and Digital Health, and are meeting with investors. However, making the right match is essential for successful partnering. We’ve broken down our registered investors, not only to show the vast diversity available at RESI, but to help attendees narrow their search for the perfect partner. Take a look at the list of registered investors here.

Make sure to check out the following links on how to be successful at partnering, and keep an eye out for our partnering tutorials to maximize your meetings!

There is still time to register before we launch partnering, register now!

AI in Diagnostics: An Investor Perspective

9 Jul

By Rory McCann, Marketing Manager & Conference Producer, LSN

It’s commonly said in business that “riches are in the niches”, which translates to targeting a specific market for an outstanding performance. In diagnostics investment, there’s no better example of this than Greybird Ventures. We spoke with the founder and CEO, Tom Miller, on his unique approach that sets his company apart in the often-competitive healthcare investment arena.

Miller started Greybird Ventures in 2013. He added two partners, and they made their first investment in 2016. Regarding their investment theme, Miller says that Greybird is, “[a] focused, totally dedicated, and only investing-in-diagnostic-technologies venture firm – we are also the world’s smallest one of those things – because I believe we’re the only ones doing that.”

Greybird’s foundation has remained the small team of three – Tom Miller, as well as Michael Devlin and Scott Gazelle – and the diagnostics-centered portfolio companies that have since grown to five, three of which work with artificial intelligence (AI)-enabled diagnostics. While the numbers may seem small, it has been an intentional strategy by Miller, who says, “[Greybird] holds a chairmanship in every firm we invest in, and we tell our CEOs who are about to take our money, ‘If you want a passive investor, don’t touch us.’ We are very active. We get involved with business development. We will help them with clinical trials. We’ll help them recruit principal investigators, and we get deeply involved in the science… That said, money is not really our limitation for how many companies we’ll invest in, but rather our own bandwidth. You don’t get a junior person. You get one of us.”

Using oncology as an example, Miller described the necessity of AI and machine learning (ML) in diagnostics. The more doctors and scientists understand certain cancers, the more specific types there are, and the broader the diagnostic range will be. Miller says, “I think within the next decade, for certain medical disciplines, practicing medicine without computerized assistance will be malpractice because you simply can’t do it.”

While a big believer in the promise of AI, Miller is skeptical of every application in the medical field, specifically in prognoses based on patient records and its potential to blur the lines between correlation and causation. He instead works to promote technologies where AI fills in the gaps, in addition to human study and close observation. Applications such as AI-enabled radiology, locating biomarkers for human cancer detection, and motion predicters to determine drug efficacy in degenerative diseases, such as Parkinson’s or Multiple Sclerosis (MS).

Just as Greybird’s success has grown in a specific space within healthcare investment, Miller believes that AI is the best solution for well-defined, narrow problems. Miller will be representing Greybird Ventures at the Inaugural 4D Meets AI digital partnering conference, September 17-18, 2020. Find out more at

The Digital Model Works If You Do it Right!

9 Jul

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The summer months may look different in 2020, but what remains the same is that there’s no rest for fundraising CEOs and investors with mandates to fill in the healthcare arena. Companies in the diagnostics, drugs, devices, and digital health realms are still chipping away at their fundraising goals, but for many, the new ecosystem of digital partnering is unknown and varies from event to event. Luckily, the most successful participants have learned how to play this new game, and there’s still time to jump in before the summer ends.

The Life Science Nation (LSN) international partnering superstructure has made LSN the premier player in the early-stage deal-making arena because LSN events connect global buyers and sellers. LSN has not been sidelined by the new business climate. On the contrary, LSN has accelerated, and is eager to share the top strategies from their playbook:

Make the Right Match.

To make the most out of a digital partnering event, it is imperative to match meetings with buyers or sellers based on development stage and product fit. LSN’s partnering system keeps a detailed up-to-date profile of the constituents so that a match can be made on fit. Matching the stage of development and product keeps the dialogue going long after the right match is made. Efficient partnering avoids the pitfall of a wasted meeting and sitting at a (virtual) table and realizing the person facing you is not a fit.

Partnering is an Ongoing Experiential Activity.

Partnering cannot be done once or twice a year, as business deals do not work that way. In the life science domain, it can take 9-18 months to put a deal together. Buyers and sellers, now more than ever, need a simple, low-cost, straightforward vehicle to meet and interact together frequently in order to find new opportunities for their respective pipelines, advance a conversation, continue to vet and develop a relationship or close a deal.

Pivot to Digital. 

Pivoting and moving from onsite gatherings to a digital format has been a major hurdle for life science conferences, but it doesn’t need to slow down partnering activities. Many large firms are trying to dock the proverbial aircraft carrier into a new berth, and need to be nimble enough to change direction and adapt quickly to the new reality. Dive into this changing landscape by joining digital partnering events and taking advantage of the flexibility digital conferences offer, such as pre-recorded panels and presentations and 24-hour partnering platform to accommodate global conversations.

The Digital Model Works, but Only if You Do, Too. 

LSN has created a new model which is a combination of extending our typical onsite one-day events into three-day virtual events, which has seen a 30% increase in attendance. Companies across life science are discovering that a hybrid business model going forward can take advantage of certain digital perks, while enjoying the in-person experience we all miss.

Check out LSN’s lineup of digital partnering events at and its Inaugural 4D Meets AI digital partnering conference at Don’t put your fundraising goals or your investments on hold like vacation plans, because unlike the summer months, the best deals won’t be back next year.

Hot Investor Mandate: USA-Based VC Invests Up to $25M in Therapeutics & Platform Technologies From Pre-Clinical to Phase 3 in All Indication Areas

9 Jul

A venture capital firm founded in the USA closed its first fund in 2017 and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest up to $25 million over the life of each portfolio company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest in North American or European companies.

The firm is focused solely on therapeutics and therapeutic platforms. The fund will invest at any stage of development from preclinical / discovery stage through Phase 3 clinical, and will invest in all therapeutic areas.

The firm can work with companies at all stages of their evolution. The firm’s team has the capability and experience to build companies from the ground up, however generally gets involved with at least the beginnings of a management team in place. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: VC Firm in USA Seeks Early-Stage Investment Opportunities in Devices, Diagnostics, Digital Health, Life Science Research Tools

9 Jul

A venture capital company based in USA manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States  and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Private Investment Firm Partnered with Strategic Partner Invests Up to $30M in Medical Devices, Also Open to Therapeutics with Established PoC

9 Jul

A private investment firm based in USA makes co-investments into early stage life science companies.  The firm prefers to invest in Series A-B rounds, and does not make seed investments.  The firm makes investments of up to $300,000 out of the firm’s own capital, and is also working with an international partner that makes investments of up to $30 million in medical devices. The firm invests in startups US-wide.

The firm invests broadly in the life sciences and will consider opportunities in therapeutics, devices, diagnostics, healthcare IT and life science tools. The firm’s partner org is focused on late stage opportunities in the electronic medical device sector and will invest up to $30 million in these opportunities, with an interest in opportunities in which this org can act as a manufacturing partner.  In other sectors, the firm makes early stage investments in companies that have established proof of concept, and interests include  orphan drugs, the microbiome, healthcare data science, tools and some devices.

The firm prefers to invest in companies that have already received a significant round of funding in the past.  For data and healthcare IT companies, initial revenues are preferred.  The firm focuses on opportunities that will provide a short path to exit. The firm takes an active role with portfolio companies, particularly in making strategic and market connections with partners in Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: